Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In single-arm Phase 2 study, Trodelvy demonstrated an ORR of 33.3 percent and a median DoR of 7.7 months, as determined by local assessment, in 108 adult TNBC patients who had previously received a median of three prior systemic therapies in the metastat...
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 22, 2022
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
Details : Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Gilead Sciences
Deal Size : $21,000.0 million
Deal Type : Acquisition
Gilead Sciences Completes Acquisition of Immunomedics
Details : Gilead gains Trodelvy, Immunomedics' lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : $15,000.0 million
October 23, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Gilead Sciences
Deal Size : $21,000.0 million
Deal Type : Acquisition
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC).
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomedic's Trodelvy™ Encouraging Early-Stage Clinical Results
Details : Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM).
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 18, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Gilead Sciences
Deal Size : $21,000.0 million
Deal Type : Acquisition
Gilead Sciences to Acquire Immunomedics
Details : Acquisition provides Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate that was granted accelerated approval by the FDA for the treatment of adult patients with metastatic triple-negative breast...
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : $15,000.0 million
September 13, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Gilead Sciences
Deal Size : $21,000.0 million
Deal Type : Acquisition
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM
Details : Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 07, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomedics Announces ASCENT Study to be Stopped for Compelling Efficacy
Details : This decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC), during its recent routine review of the ASCENT study.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
Details : Patient enrollment into the Phase 3 TROPiCS-02 study of Trodelvy in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, has been resumed at approximately 20 clinical sites as of mid-May.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Dla Piper
Deal Size : $483.3 million
Deal Type : Public Offering
DLA Piper Advises Immunomedics in its US$483 Million Follow-On Offering
Details : Immunomedics intends to use the net proceeds from the offering to support the commercial launch of Trodelvy to treat metastatic triple-negative breast cancer, continue expanding the clinical development programs for Trodelvy.
Product Name : Trodelvy
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Dla Piper
Deal Size : $483.3 million
Deal Type : Public Offering